These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23670789)

  • 1. Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.
    Anderson MS; Cote J; Liu Y; Stypinski D; Auger P; Hohnstein A; Rasmussen S; Johnson-Levonas AO; Gutstein DE
    J Clin Pharmacol; 2013 Jul; 53(7):746-52. PubMed ID: 23670789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
    Krishna R; Bergman AJ; Jin B; Garg A; Roadcap B; Chiou R; Dru J; Cote J; Laethem T; Wang RW; Didolkar V; Vets E; Gottesdiener K; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.
    Eley T; Han YH; Huang SP; He B; Li W; Bedford W; Stonier M; Gardiner D; Sims K; Rodrigues AD; Bertz RJ
    Clin Pharmacol Ther; 2015 Feb; 97(2):159-66. PubMed ID: 25670521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
    Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
    Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.
    Shitara Y
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):220-7. PubMed ID: 21297316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.
    Choi MK; Jin QR; Choi YL; Ahn SH; Bae MA; Song IS
    Biopharm Drug Dispos; 2011 Apr; 32(3):175-84. PubMed ID: 21456052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hepatic uptake transporters by flavonoids.
    Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
    Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
    Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
    J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
    Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
    Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.
    Cardona P; Dutta S; Houk B
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):810-818. PubMed ID: 38421129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
    Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
    Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
    Chen H; Chen W; Li H; Xu H; Yuan F; Sheng L; Liu C; Lin P; Yang M; Li X; Liu Y; Walker BM; Gheyas F; Iwamoto M; Stoch SA; Krishna R
    Adv Ther; 2021 Jul; 38(7):3973-3985. PubMed ID: 34101144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Jin B; Keshavarz SS; Bieberdorf FA; Chodakewitz J; Wagner JA
    Br J Clin Pharmacol; 2009 May; 67(5):520-6. PubMed ID: 19552746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Gendrano IN; Maes A; DeGroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.